Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Synuclein
Anti-Synphilin 1 antibody
See all Synphilin 1 products (6) ...
Mouse monoclonal to Synphilin 1
Reacts with
Human
Recombinant fragment, corresponding to amino acids 206-310 of Human Synphilin 1
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Preservative: None
PBS, pH 7.2
Concentration information loading...
Protein G purified
Monoclonal
IgG1
kappa
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Other
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Synuclein
Western blot - Synphilin 1 antibody (ab56627)
(enlarge)
Our Abpromise guarantee covers the use of ab56627 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 1-5 µg/ml.
This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1.
Detected in brain (at protein level). Widely expressed, with highest levels in brain, heart and placenta.
Defects in SNCAIP may be a cause of Parkinson disease (PARK) [MIM:168600]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.
Contains 6 ANK repeats.
Ubiquitinated; mediated by SIAH1, SIAH2 or RNF19A and leading to its subsequent proteasomal degradation. In the absence of proteasomal degradation, ubiquitinated SNCAIP accumulates in cytoplasmic inclusion bodies. Isoform 2 is subject to limited ubiquitination that does not lead to proteasomal degradation.
Cytoplasm. Detected in cytoplasmic inclusion bodies, together with SNCA.
Target information above from: UniProt accessionQ9Y6H5
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Western blot - Synphilin 1 antibody (ab56627)

Western blot against tagged recombinant protein immunogen using ab56627 Synphilin 1 antibody at 1ug/ml. Predicted band size of immunogen is 38 kDa
ab56627 has not yet been referenced specifically in any publications.
Publishing research using ab56627? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
